<DOC>
	<DOCNO>NCT00683969</DOCNO>
	<brief_summary>The efficacy safety CellCept ( 1g po , bid 36 week ) assess patient myasthenia gravis receive prednisone , corticosteroid . During study , patient undergo gradual corticosteroid dose reduction , respond treatment . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Assess Effect CellCept ( Mycophenolate Mofetil ) Reduced Corticosteroids Controlling Symptoms Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient 18 80 year age ; diagnosis myasthenia gravis ; history myasthenia weakness involve ocular ( ie eye ) periocular muscle ; duration myasthenia gravis symptom ( include ocular symptom ) &lt; =10 year ; prednisone dose &gt; =20 mg/day ( equivalent alternateday dose ) &gt; =4 week . female patient pregnant , breastfeeding , lactate ; regularly schedule plasma exchange ( PE ) intravenous immunoglobulin ( IVIG ) treatment , PE IVIG treatment within 2 week prior randomization ; prior clinically significant use CellCept immunosuppressive therapy ( except corticosteroid ) , within 8 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>